Treatment of deep-seated facial microcystic lymphatic malformations with intralesional injection of pingyangmycin.
Treatment of deep-seated facial microcystic lymphatic malformations with intralesional injection of pingyangmycin.
复制标题
平阳霉素病灶内注射治疗面部深部微囊性淋巴管畸形
DOI：
10.1097/md.0000000000004790
复制
发表时间：
2016-09
期刊：
影响因子：
1.6
通讯作者：
Fan XD
中科院分区：
文献类型：
--
作者：
Wu HW;Wang X;Zheng JW;Zhao HG;Ge J;Zhang L;Wang YA;Su LX;Fan XD
摘要微囊性淋巴管畸形(LMS)的治疗仍然是血管畸形医生面临的一大挑战。已经提出了几种治疗微囊型LMS的方法，但对这些治疗方式的反应在个体之间差别很大。本研究的目的是探讨平阳霉素病灶内注射治疗面深部微囊性LMS的安全性和有效性。自2010年3月至2015年4月，连续21例面部深部微囊性LMS患者接受了平阳霉素病灶内注射治疗。患者接受2~8次注射，平均3.7次。根据影像表现和临床测量结果评价治疗效果。21例中，优7例(33.33%)，良9例(42.86%)，可3例(14.29%)，差2例(9.52%)。未见严重副作用。此外，治疗结果与病变部位(P = 0.006)和注射次数(P = 0.003)显著相关。我们的研究支持平阳霉素硬化疗法治疗面部深部微囊性LMS是安全有效的。
Abstract Treatment of microcystic lymphatic malformations (LMs) is still a great challenge to physicians in the field of managing vascular anomalies. Several kinds of treatment have been proposed for microcystic LMs, but the responses to these treatment modalities vary considerably among individuals. The aim of the study was to investigate the safety and efficacy of intralesional injection of pingyangmycin for microcystic LMs located in the deep facial region. Twenty-one consecutive patients with deep-seated facial microcystic LMs were treated with intralesional injection of pingyangmycin between March 2010 and April 2015. The patients received 2 to 8 injections, and the average session was 3.7. The therapeutic efficacy was accessed on the basis of the imaging findings and clinical measurements. Among the 21 patients, the clinical responses were excellent in 7 patients (33.33%), good in 9 patients (42.86%), fair in 3 patients (14.29%), and poor in 2 patients (9.52%). No severe side effects were encountered. Furthermore, therapeutic outcomes were significantly associated with lesion location (P = 0.006) and number of injections (P = 0.003). Our study supports that sclerotherapy with pingyangmycin is safe and effective for the treatment of deep-seated facial microcystic LMs.